Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Symptomatic diastolic heart failure

• Breathlessness with physical exertion

Exclusion Criteria:

• Uncontrolled hypertension

• Asthma, COPD, or abnormal lung function

• History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm

• Liver, kidney, or pancreas disease

• Allergy to valsartan

Other protocol-defined exclusion criteria may apply